Court (case ID: 14 W (pat) 23/24). The case primarily concerns second medical use claims. Enforcing second medical use patents is currently contentious, as absolute substance protection is due to
Recently, the Munich local division of the Unified Patent Court (UPC) ruled the second medical use patent for cabazitaxel (EP 2 493 466) held by Sanofi invalid, determining that the patent lacks
total 1 pages, 2 items